A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
BRF113710 is a Phase II, single-arm, open-label study to assess the efficacy, safety, and
tolerability of GSK2118436 administered twice daily as a single agent in subjects with BRAF
mutant metastatic melanoma. Subjects will receive 150 mg of GSK2118436 twice daily and
continue on treatment until disease progression, death, or unacceptable adverse event.